The Effect of Tasisulam on CYP3A-mediated Metabolism of Midazolam: A Pharmacokinetic Interaction Study in Cancer Patients With Advanced and/or Metastatic Tumors or Lymphoma.
Phase of Trial: Phase I
Latest Information Update: 12 Apr 2011
At a glance
- Drugs Midazolam; Tasisulam
- Indications Lymphoma; Pain; Solid tumours
- Focus Pharmacokinetics
- 12 Apr 2011 Planned End Date changed from 1 Sep 2012 to 1 Jan 2011 as reported by ClinicalTrials.gov.
- 12 Apr 2011 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
- 01 Dec 2010 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.